PARP inhibitors work only against prostate cancers with BRCA or HRR mutations—a December 2025 FDA approval added a BRCA2 hormone-sensitive option.

Immunotherapy for prostate cancer works differently than chemo: Provenge may extend survival even when scans don't shrink. Here's what that means for you.

Pluvicto, a lutetium-177 radioligand therapy, targets PSMA-positive metastatic prostate cancer — here's how it works and who qualifies.

Hearing 'chemo' for prostate cancer is frightening, but it's used only when the cancer has spread—often with hormone therapy. See when it helps and how.

Hormone therapy slows prostate cancer by lowering testosterone, but how long you stay on it ranges from months to years. Here's what to expect.

Radiation therapy for prostate cancer isn't one option but several, each with a different risk profile—from IMRT and SBRT to brachytherapy and Pluvicto.

Radical prostatectomy recovery follows a clear arc—catheter out around 1–2 weeks, then continence and PSA milestones. Here's what to expect at each stage.

Active surveillance lets men with Gleason 6 prostate cancer monitor instead of treating now—see who qualifies and how it's tracked.

rostate cancer screening isn't one age for everyone. Most men start at 50, but higher-risk men begin at 45 or 40 — see where you fall.

Prostate cancer hits 1 in 6 Black men—the largest racial gap of any major cancer. Caught early, it's highly treatable. Here's when to screen.